SCHEMBL17830720

SCHEMBL17830720

COc1cccc(COC(=O)Cn2c(=O)oc3cc(Cl)ccc32)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.56
LMNA P02545 1/20 0.56
IDO1 P14902 1/20 0.55
POLB P06746 2/20 0.52
MAPT P10636 1/20 0.52
CDYL2 Q8N8U2 3/20 0.51
CDYL Q9Y232 3/20 0.51
CDY1; CDY1B Q9Y6F8 3/20 0.51
MIF P14174 3/20 0.51
CD74 P04233 2/20 0.51
TNIK Q9UKE5 2/20 0.51
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CBX7 O95931 2/20 0.48
RECQL P46063 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 1/20 0.48
CCR2 P41597 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830725 0.90 POLB (0.52) TP53LMNAIDO1POLBMAPT
SCHEMBL17830721 0.89 TP53 (0.59) TP53LMNAPOLBMAPTUSP2
SCHEMBL17830723 0.88 PKM (0.53) TP53LMNAIDO1POLBMAPT
SCHEMBL17830736 0.88 MIF (0.52) TP53LMNAIDO1POLBMAPT
SCHEMBL17830715 0.86 PIK3CB (0.54) TP53IDO1POLBMAPTMIF
SCHEMBL17830727 0.86 IDO1 (0.55) TP53LMNAIDO1POLBMAPT
SCHEMBL17830735 0.84 CCR2 (0.48) TP53LMNAIDO1POLBMAPT
SCHEMBL17830724 0.84 IDO1 (0.51) TP53LMNAIDO1POLBMAPT
SCHEMBL17830729 0.83 CYP1A2 (0.45) TP53LMNAIDO1POLBMAPT
SCHEMBL17830722 0.82 RECQL (0.55) TP53LMNAPOLBMAPTMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A TP53 158/4885LMNA 3890/4885IDO1 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.